Dysmenorrhea (pain with menstruation) affects up to 90% of adolescent and young women. Despite the availability of a variety of effective pharmacological treatments, it is frequently left untreated. Non-steroidal anti-inflammatory drugs (NSAIDs) are the best-established initial therapy for dysmenorrhoea. When NSAIDs are given through the oral route, it causes several side-effects like gastric disturbance, stomach ulcer, nausea, vomiting, etc. Piroxicam is an NSAID utilized for treating dysmenorrhoea in the form of tablet formulation. As mentioned above, it also suffers from similar adverse effects. To overcome those conditions, the transdermal patch of piroxicam can serve as a better alternative to the tablets which serves as the safe alternative over oral route. In the present research, the transdermal patch of piroxicam was fabricated by using controlled release hydrophilic and lipophilic polymers containing permeation enhancer and thoroughly evaluated. The transdermal patches of piroxicam were prepared using the combination of polymers, HPMC, PVP, and EC in different concentration with SLS as the permeation enhancer and polyethylene glycol 400 as the plasticizer was used for the formulation of TDDS which demonstrated control release of drug through the patches. The formulation F1 containing hydrophilic and lipophilic polymers (3:1 ratio) showed maximum release and permeation of drug for a longer time period up to 12 hrs which made it suitable for the development of controlled release patches of piroxicam.
Key words: Dysmenorrhea; Piroxicam; Transdermal; Patch; NSAID; Controlled